Intradermal Rabies Immunization Using NanoJect: A Comparative Study

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies vaccine \"Vaccin rabique Pasteur®\" delivered with the NanoJect™ device by ID route.
Epistemonikos ID: 19f25522756290ef834931c29676b5756df94097
First added on: May 12, 2024